<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prognosis for higher risk childhood B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has improved over the past 20 years but the optimal intensity of treatment has yet to be determined </plain></SENT>
<SENT sid="1" pm="."><plain>Children 21 years old or younger with newly diagnosed B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (B-NHL/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) with higher risk factors (bone marrow [BM] with or without <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement) were randomized to standard intensity French-American-British/<z:hpo ids='HP_0002665'>Lymphoma</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Malignancy</z:e> B (FAB/LMB) therapy or reduced intensity (reduced <z:chebi fb="0" ids="28680">cytarabine</z:chebi> plus <z:chebi fb="0" ids="4911">etoposide</z:chebi> and deletion of 3 maintenance courses M2, M3, M4) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease had additional high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (8 g/m2) plus extra intrathecal therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty-one percent had BM involvement, 20% had <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement, and 29% had BM and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement </plain></SENT>
<SENT sid="4" pm="."><plain>One hundred ninety patients were randomized </plain></SENT>
<SENT sid="5" pm="."><plain>The probabilities of 4-year event-free survival (EFS) and survival (S) were 79% +/- 2.7% and 82% +/- 2.6%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In patients in remission after 3 cycles who were randomized to standard versus reduced-intensity therapy, the 4-year EFS after randomization was 90% +/- 3.1% versus 80% +/- 4.2% (one-sided P = .064) and S was 93% +/- 2.7% versus 83% +/- 4.0% (one-sided P = .032) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with either combined BM/<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease at diagnosis or poor response to <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, Oncovin [<z:chebi fb="0" ids="28445">vincristine</z:chebi>], <z:chebi fb="0" ids="8382">prednisone</z:chebi> (COP) reduction therapy had a significantly inferior EFS and S (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> with or without <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement) </plain></SENT>
</text></document>